- Home
- TTRX vs ALLO Comparison
TTRX vs ALLO Comparison
Compare TTRX & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTRX
- ALLO
- Stock Information
- Founded
- TTRX 2015
- ALLO 2017
- Country
- TTRX United States
- ALLO United States
- Employees
- TTRX N/A
- ALLO N/A
- Industry
- TTRX Biotechnology: Pharmaceutical Preparations
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TTRX Health Care
- ALLO Health Care
- Exchange
- TTRX Nasdaq
- ALLO Nasdaq
- Market Cap
- TTRX 257.8M
- ALLO 252.9M
- IPO Year
- TTRX N/A
- ALLO 2018
- Fundamental
- Price
- TTRX $4.55
- ALLO $1.22
- Analyst Decision
- TTRX
- ALLO Buy
- Analyst Count
- TTRX 0
- ALLO 12
- Target Price
- TTRX N/A
- ALLO $8.80
- AVG Volume (30 Days)
- TTRX 2.1M
- ALLO 3.1M
- Earning Date
- TTRX 01-01-0001
- ALLO 11-06-2025
- Dividend Yield
- TTRX N/A
- ALLO N/A
- EPS Growth
- TTRX N/A
- ALLO N/A
- EPS
- TTRX N/A
- ALLO N/A
- Revenue
- TTRX N/A
- ALLO N/A
- Revenue This Year
- TTRX N/A
- ALLO N/A
- Revenue Next Year
- TTRX N/A
- ALLO $100.00
- P/E Ratio
- TTRX N/A
- ALLO N/A
- Revenue Growth
- TTRX N/A
- ALLO N/A
- 52 Week Low
- TTRX $4.18
- ALLO $0.86
- 52 Week High
- TTRX $26.50
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- TTRX N/A
- ALLO 47.02
- Support Level
- TTRX N/A
- ALLO $1.21
- Resistance Level
- TTRX N/A
- ALLO $1.33
- Average True Range (ATR)
- TTRX 0.00
- ALLO 0.10
- MACD
- TTRX 0.00
- ALLO -0.02
- Stochastic Oscillator
- TTRX 0.00
- ALLO 8.82
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.